Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Clinical Trials are divided into the following categories:
A potential new treatment for advanced ovarian, peritoneal or fallopian tube cancer.
The purpose of this study is to test a potential new treatment for ovarian, peritoneal or fallopian tube cancer called ZN-c3-also known as azenosertib. This study that will investigate the study drug ZN-c3 to find out if it is safe and whether it will slow or stop the spread of your cancer when taken in combination with chemotherapy such as PLD (pegylated liposomal doxorubicin), Paclitaxel, carboplatin, or gemcitabine.